Among the various lipophilic building blocks within the linker of the PSMA inhibitor series, PSMA-617 showed the best combination of activity in tumor tissues and renal excretion with its linker consisting of 3-(2-naphthyl)-alanine (2NaI) and trans-4-(aminomethyl)cyclohexane carboxyamide (ChX). This evidence concerns the gene FOLH1 and neoplasm.